these therapies available as quickly as possible."

Patients who would like to find out more about biological therapy are advised to talk to their dermatologist.

In the European Union, Enbrel? is approved for the treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (Psoralen (a light-sensitizing medication) combined with exposure to ultraviolet light A (UVA). Enbrel is also approved for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate.

Physicians in Europe have become familiar with the benefits and long-term tolerability profile of ENBREL since it became commercially available over six years ago. More than 400,000 patients have been treated worldwide across indications. Enbrel is a recombinant human tumour necrosis factor (TNF) receptor fusion protein that inhibits the activity of TNF. TNF is a cytokine that is released from T lymphocytes; it mediates inflammation and modulates the cellular immune response. Enbrel is also indicated for treatment of the following:

Severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Active Juvenile Idiopathic Arthritis in children aged 4 to 17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Enbrel has not been studied in children aged less than 4 years. Severe active ankylosing spondylitis in adults who have had an inadequate response to conventional therapy.

Since the product was first introduced, serious infections, some involving death, have been reported in patients using ENBREL. Patients should tell their doctor if they currently have an infection or are prone to getting infections. Patients should not sta
'"/>




Page: 1 2 3 4
Related medicine news :

1. Vitamin E supports Female Hearts
2. Injection supports Heart Devices
3. Study supports vegetable diet
4. Study supports century-old cancer theory
5. Novartis files application with FDA for Zometa
6. Morepan to file new drug applications with the USFDA
7. Mini motor for micromedical applications
8. Perfusion bioreactor could enhance stem cell research and application in the future
9. Innovative device aids in advanced heart failure
10. Light therapy devotes new hope in advanced lung cancer
11. Race an important links to the risk of advanced colorectal cancer